The current study elucidates the contributory role of SMAD3 in NSCLC radioresistance, delineating the mechanism wherein enforced SMAD3 expression activates the ITGA6/PI3K/Akt pathway, thereby intensifying NSCLC radioresistance. Here, SMAD3 is linked to non-small cell lung carcinoma.